stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) Return on assets
Takeda Pharmaceutical Co.'s return on assets over the twelve months to 30 September 2026 was 0.00%, up 1.0 percentage points from fiscal 2026 (−1.02%). Over the past ten years it has ranged from −3.13% (fiscal 2015) to 4.34% (fiscal 2018); the current reading is higher than 17% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −1.67% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2026 | −1.02% | (1.74) |
| FY2025 | 0.72% | (0.24) |
| FY2024 | 0.96% | (1.17) |
| FY2023 | 2.13% | 0.41 |
| FY2022 | 1.72% | (1.23) |
| FY2021 | 2.95% | 2.61 |
| FY2020 | 0.34% | (0.87) |
| FY2019 | 1.21% | (3.13) |
| FY2018 | 4.34% | 1.38 |
| FY2017 | 2.96% | 1.08 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ZTS Zoetis Inc. compare | 17.8% |
| UTHR United Therapeutics Corporation compare | 17.1% |
| NBIX Neurocrine Biosciences, Inc. compare | 14.2% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.44% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 1.27% |
| TAK Takeda Pharmaceutical Co. | 0.00% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| ELAN Elanco Animal Health Incorporated compare | −1.46% |
| VTRS Viatris Inc. compare | −1.67% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on TAK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement